Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-Positive Breast Carcinoma: early-phase trial registry
4 of 13 indexed HER2-Positive Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count
HER2-Positive Breast Carcinoma: 13 US clinical trials tracked, 4 recruiting.
HER2-Positive Breast Carcinoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition her2-positive-breast-carcinoma
OPEN 4 | RECR 31% | LATE 1 | EARLY 9 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)
HER2-Positive Breast Carcinoma lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-Positive Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-Positive Breast Carcinoma is recruiting below its size-band peers.
4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HER2-Positive Breast Carcinoma research.
Mayo Clinic accounts for 3 of 13 trials (23.1%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most HER2-Positive Breast Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
HER2-Positive Breast Carcinoma research is mostly interventional.
11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Mayo Clinic
NCT04517838
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
M.D. Anderson Cancer Center
NCT02945579
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
Mayo Clinic
NCT06557057
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
NCT04550494
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
ECOG-ACRIN Cancer Research Group
NCT05710328
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03384914
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
University of Alabama at Birmingham
NCT03368729
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
NCT02827877
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
NCT02654119
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
George W. Sledge Jr.
NCT03364348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-Positive Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-Positive Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-Positive Breast Carcinoma page
13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 HER2-Positive Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most HER2-Positive Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-Positive Breast Carcinoma condition card totals 13 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.